Upload
claudiopramirez
View
2.055
Download
2
Tags:
Embed Size (px)
DESCRIPTION
Canada's life sciences industry strengths
Citation preview
Canada: Florida’s Innovation, Investmentand International Biotech Partner
Canada: Florida’s Innovation, Investmentand International Biotech Partner
Life Sciences BreakfastTampa, February 1, 2010
2
Overview
� Background� Canada� Florida� Opportunities� Partnerships
BackgroundBackground
4
Department of Foreign Affairs andInternational Trade Canada (DFAIT)
Canada has diplomatic and consular offices in over270 locations in 180 countries.
Canada has diplomatic and consular offices in over270 locations in 180 countries.
5
Canada’s Footprint in North America
6
Canada-U.S. Relations
� Canada and the U.S., a strong partnership
� Geography, History, Security and Business
� Canada is Florida’s #1 Economic Partner
� Common industrial strengths, both dependheavily on international commerce
� Canada 8th largest economy worldwide,Florida about 15th.
7
Mexico City
1000 km
500 km
Los Angeles
Denver
Houston
Atlanta
Seattle
Miami
New YorkBoston
Philadelphia
WashingtonBaltimore
DetroitChicago Cleveland
St. LouisPittsburgh
Milwaukee
San Francisco
St. John's
CalgaryVancouver
ReginaHalifax
TorontoMontréal
WinnipegCharlottetown
Edmonton
Victoria Ottawa
Windsor
QuébecFredericton
Saskatoon
Market Access
8
Largest Trading Partner
9
Investment = Influence
Largest Foreign Investor
10
Top Foreign Investors in FloridaBy Value (billions) By Jobs
Germany $3.8 UK 45,200
Japan $3.79 Netherlands 24,000
UK $3.69 Canada 23,100
Canada $2.99 Germany 22,400
Australia $2.77 Japan 21,20
A Top Investor in Florida
11
Canadian Businesses
12
Canadian Businesses
CanadaCanada
Canadian Health Care Market
� Population: 33.5 million
� High health expenditure: CAD $5170 p.p.
� Long life expectancy: 81.6 years
� $20B drug market, $6B in medical devices, Top 10 globally
� Highly profitable: 13% average profit margins
� Bio-based economy worth $78.3 billion (6.5% of GDP, similar insize to auto) and is responsible for 1 million jobs.
15
Industry Snapshot
� Home to 3rd largest Life Sciences industry in the world
� Key strengths:� Biopharmaceutical R&D� Medical devices� Contract services
� Leading scientific excellence
16
British Columbia•110 companies
•2500 employees (15%)
•$300 M in annual R&D
• Genomics
Ontario:•220 companies
•6000 employees (38%)
•$650 M in annual R&D
• Stem Cells
• Drug Development
Atlantic Canada•30 companies
•200 employees (1%)
•$25 M in annual R&D
• Nutraceuticals &Marine Bioscience
Quebec•240 companies
•5500 employees (35%)
•$600 M in annual R&D
• Vaccine Research
Prairies•110 companies
•1800 employees (11%)
•$200 M in annual R&D
• Bioimaging
Source: Industry Canada, Statistics Canada, PMPRB. Statistics are for Private sector only
Life Science Clusters In Canada
17
Pharmaceutical Industry Snapshot
� $20 billion domesticmarket
� 100+ companies with40,000+ employees
� Market dominated byforeign multinationals
� $1.5 billion in R&Dspending
� Over $4 billion in exports
18
Consumer Pharmaceutical Spending
� Total annual spending (prescription drugs): $19.3 billion�Brand name: $15.2 billion (78.6%)�Generic: $4.1 billion (21.4%)
Average cost per prescription, $CAD
Biopharmaceutical Industry Strengths
• Discovery & characterization of therapeutic molecules
• Genomics & proteomics platforms
• Vaccines & immuno-therapeutics
• Regenerative medicine & stem cell research
• Drug formulation & delivery systems
• Oncology/cancer research
• Generic pharmaceuticals
20
Major Global Investors in Canada
21
Top Sales Leaders in 2008
Ran
k LeadingCompanies
R&D Locationin Canada
TotalPurchases($ Billions)
MarketShare (%)
1 Pfizer Montreal 2.57 12.7
2 Apotex Toronto 1.52 7.5
3 AstraZeneca Montreal 1.34 6.6
4 Johnson & Johnson Toronto 1.10 5.5
5 GlaxoSmithKline Toronto 0.97 4.8
6 Novopharm Toronto 0.83 4.1
7 Novartis Toronto 0.75 3.7
8 Abbott Montreal 0.72 3.6
9 Schering-Plough Montreal 0.68 3.4
10 Roche Montreal 0.62 3.1
Leading Pharmaceutical Companies in Canada in 2008
� Sanofi Pasteur• $100M: vaccine R&D facilities in Toronto
� AstraZeneca Canada Inc.• $10M: pain control research centre in Montreal
� Glaxo Smith Kline (GSK)• $199M: vaccine production facility in Québec• $50M: vaccine R&D headquarters in Montreal
Recent Investments In Canada
23
Leading Canadian Companies(Some Examples)
Company Focus
Apotex Generics manufacturing
Amorfix Theranostics: detection of proteinmisfolding
Biovail CNS disorders, pain management, &cardiovascular disease
BioNiche Life Sciences Oncology & animal vaccines
Cangene Mfg. of Ab.’s, peptides, & vaccines
DiaMedica Therapy for Type II diabetes
ImmunoVaccineTechnologies Vaccine innovation & development
Labopharm Controlled-release technologies forsmall molecule drugs
NAEJA NCE discovery & synthesis
Prometic Life Sciences Mfg of natural, recombinant, &synthetic proteins
Theratechnologies Peptide-based therapeutics
24
Medical Device Industry Snapshot
� $6 billion market
� $2 billion in exports; $4 billion inimports
� Majority of revenues tomultinationals & distributors
� 200+ developers/manufacturers(90% Canadian owned)
� 94% of firms have < 50 employees
25
Major Global Investors in Canada
26
Company Focus
Angiotech TAXUS® drug-elutingcoronary stent
ART Optical molecular imaging
EastMed Uresta® bladder support
Epocal Blood diagnostic system inFlexCard™ technology
IMRIS IMRISneuro, Intra-operative MRI
MDS Nordion Radiological imaging &isotopes
NovadaqTechnologies Operating room imaging
Pyng Medical First Aid Devices
Resonant Medical 3D Ultrasound Imaging
Urodynamix Urology diagnostics
Leading Canadian Companies(Some Examples)
27
Leading Canadian Companies(Some Examples)
Company Focus
Axela Protein interaction technology
BrightWELLTechologies
Micro-Flow imaging technology(MFI) for cell analysis
DNA Genotek DNA collection & preservationsystems
QBM Cell Science Cryopreserved mouse neurons
Rimon Therapeutics Advanced medical polymers &biomaterials for wound care
Spartan Biosciences Personal DNA analyzers
Spectral Diagnostic Fast testing of Sepsis & WestNile Virus
28
Medical Device Strengths
�In-vitro diagnostics
�Medical imaging & analysis
�Nuclear medicine
�Surgical & implant devices
�Advanced materials & nanotechnology
29
In-Vitro Diagnostics
Epocal’s Blood DiagnosticSystem in FlexCard™
Technology
Examples Include:
Spectral Diagnostic’sTesting Kit for West Nile
Virus
30
Medical Imaging & Analysis
ART’s SoftScanBreast Imaging Device
Examples Include:
IDC’s DR System
31
Nuclear Medicine
MDS Nordion’s Glucotrace® for Cardiology andOncology Diagnoses using PET Isotopes
Examples Include:
32
Surgical & Implant Devices
Angiotech’sDrug-Eluting
CoronaryStents
Examples Include:
EastMed’s Uresta® for Stress UrinaryIncontinence for Women
33
Latest Innovation
World’s First Simulation-Based Brain Surgery Done in Halifax, Canada2009.08
THEN: Provided backup supply services to multinational
pharmaceutical companies
NOW: Grown and become technologically sophisticated
� World renowned for quick recruiting
� Adheres to GCP protocols & generates high quality, robustdata
� 4th worldwide in overall share of global clinical trials
� Top 10 pharmaceutical companies consistently includeCanada in clinical development plans & new drug submissiondata packages
Canada’s Contract Services Subsector
35
�Contract manufacturers (CMOs)
�Clinical research organizations(CROs)
�Design & manufacturing of highvalue medical devices (surgicaldevices, implants, imaging systems)
�Analytical services
�Regulatory affairs & compliance
Contract Services: Strengths
36
Leading Canadian Companies
Company Focus
Algorithme Pharma Research contracting organization specializing in pre-clinical, phase I & bioequivalencestudies
Allphase Clinical Research Clinical trial management company managing multi-site trials & sourcing trial servicesglobally
Biovectra Manufacturing contracts for both large and small-molecule Advanced PharmaceuticalIngredients (API’s), advanced intermediates, and cGMP bioprocessing reagents
MDS Pharma Service Research contracting organization that provides drug discovery and development services
Therapure BiopharmaManufacturing contractors committed to the development, manufacturing, purification, and
packaging of high-quality biological therapeutics
Wellspring Pharmaceutical Manufacturing contracts for specialized dosage forms for clinical & commercial distribution
37
Clinical Trials by Condition
Source: ClinicalTrials.gov, Dec. 2008
38
Clinical Trials by Sponsor
FloridaFlorida
40
Emerging Biotech Cluster
� Why is Canada interested?� Top 10 US biotech clusters
� US $10b+ NIH funding, most researchintensive country in the world, 50% and 40%of global patent applications in med techand pharma/biotech products, respectively
� Paradigm shift: globalization of industry andBigPharma looking to fill innovation gap asblockbuster revenue cliff approaches
� Weaknesses in Florida� VC funding
� Training/Tertiary Education/Skilled Labour
� Entrepeneurship
OpportunitiesOpportunities
42
� Post-recession• Technology based firms need international linkages to position themselves for the
post-recession economy.• By partnering with other countries on science and technology, firms connect to
knowledge, know-how, people, investments and markets abroad.• They also respond to new business model where “biotech clusters will be
redefined away from geography and be more virtual built around diseases,pathways, markets, and unique industry segments”. (Burrill & Co. Biotech 2010 –Life Sciences: Adapting for Success).
� Credit Crunch, Public & Private Capital Drought• VC funding lowest in 15 years both in Canada and the U.S.: ($1 billion in Canada,
$235 million in Florida) – however healthcare surpassed IT or cleantech.• PE/Buyout market: Canada 4th in volume, 18th in value of M&A deals, however
Canadian funds raised close to $20 billion in 2006-2008 so considerable availablecapital to deploy.
• Only 3 biotech IPOs in 2009, but Burrill expects pick-up to 15 IPOs in 2010
Strategic Context
43
Five major factorsdrive foreign interest in collaborations
• Strong and stable economy• First-class technological infrastructure• Highly skilled workforce• Lower business and R&D cost structure• Investment incentive programs: the best
research incentives in the world
Attractions include Canada’s:
44
Workforce: Educated & Available
Higher Education Achievement
54,0 53,051,4 51,0 50,0
47,8
41,0 41,0 41,0 40,0 40,0 39,8 39,0 39,0
30
35
40
45
50
55
Canada
Japan
Singap
oreSout
h Korea
Israel
Taiwan
Belgium
Irelan
dNorw
ayDen
markSpai
nHon
g Kong
France U.S.
%
Source: IMD, World Competitiveness Yearbook 2008
45
Workforce: Educated & Available
Source: IMD, World Competitiveness Yearbook 2008
46
Low Labor Costs
47
Thriving Clusters
48
Quality Living Environment
49
Canada: An Innovation Leader
� Canada generates about 4% of global knowledge, as measured byacademic publications, a formidable statistic considering itcomposes only 1% of the global population.
� Canada leads the G7 in public sector research funding on a percapita basis.
� Canada has one of the most generous tax-based supportprograms in the industrialized world through the ScientificResearch & Experimental Development tax credit.
50
Canadian Life Sciences Innovation
� Canada’s health science research community consists of over64,000 physicians, 30,000 investigators in 17 medical schools, andover 100 teaching hospitals and research institutes.
� Canadian innovators are internationally recognized for researchand product development excellence in genomics,proteomics,vaccine development, medical devices, regenerative medicine(stem cells), protein engineering, immunotherapies and drugdelivery systems.
� Canada Canadian life sciences discoveries: insulin, pacemaker,sequencing Alzheimer genome & H1N1 genome, adult stem cells,how stem cells become blood cells, embryonic stem cells fromskin, etc.
51
Canadian university R&Dfunding programs
• Canadian Institutes of Health Research (CIHR)• Canada Foundation for Innovation (CFI)• Canada Research Chairs (CRC)• Genome Canada• Networks of Centres of Excellence (NCE)• Department of Foreign Affairs and International Trade• National Research Council:
• 15 Industrial Partnership Facilities (IPF)business incubators affiliated with NRC’s 21research institutes -137 firms, 13 graduates 08-09• Industry Research Assistance Program (IRAP)works with 8000 SMEs, youth internships, Angiotech (anti-
inflammation tech) in 5 years $30 milllions 1,500 jobs
52
$
Mind Market
Public
Private
Life Sciences
ICT
Clean Tech
Aerospace
Valley of
Death
Innovation and Sector Interface
53
� Growth Capital
Investment
2009
TSX: 28 IPOs, $1.8billion
TSX-V: 20 IPOs, $69 million
2010 (projected)
TSX & TSX-V: $4 billion IPO market
54
� BioPartnering North America, Vancouver, Jan 24-26, 2010
� BioFinance, Toronto, 6-8 April, 2010
� BioContact, Quebec City, Oct. 6-7, 2010
Events in Canada
PartnershipsPartnerships
56
� Stem Cells
Success Stories
57
� Drug Development
Success Stories
58
� Research/Education/Simulation/Commercialization
Success Stories
59
� AIDS/Immunology
Success Stories
60
� And more…
Success Stories
61
� Tap into Canadian ideas, knowledge and talent – throughstrategic alliances, joint ventures, licensing and technologytransfer agreements, and venture capital as well as public andprivate equity investments.
� Explore the opportunities to make Canadian innovators yourtechnology development and commercialization partners.
Conclusion
http://twitter.com/claudiopramirez
http://www.linkedin.com/in/claudiopramirez
http://www.facebook.com/claudiopramirez
Contact Info